Ketolide treatment of Haemophilus influenzae experimental pneumonia

Antimicrob Agents Chemother. 1999 Mar;43(3):708-10. doi: 10.1128/AAC.43.3.708.

Abstract

The MICs of HMR 3004 and HMR 3647 at which 90% of beta-lactamase-producing Haemophilus influenzae isolates were inhibited were 4 and 2 micrograms/ml, respectively. Both HMR 3004 and HMR 3647 were active against beta-lactamase-producing H. influenzae in a murine model of experimental pneumonia. As assessed by pulmonary clearance of H. influenzae, HMR 3004 was more effective (P < 0.05) than was azithromycin, ciprofloxacin, clarithromycin, erythromycin A, pristinamycin, or HMR 3647 in this model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Colony Count, Microbial
  • Drug Resistance, Microbial
  • Haemophilus Infections / drug therapy*
  • Haemophilus Infections / microbiology
  • Haemophilus influenzae* / drug effects
  • Haemophilus influenzae* / enzymology
  • Haemophilus influenzae* / isolation & purification
  • Humans
  • Ketolides*
  • Macrolides*
  • Mice
  • Mice, Inbred C57BL
  • Pneumonia, Bacterial / drug therapy*
  • Pneumonia, Bacterial / microbiology
  • beta-Lactamases / metabolism

Substances

  • Anti-Bacterial Agents
  • Ketolides
  • Macrolides
  • RU 64004
  • beta-Lactamases
  • telithromycin